Dr E MacLeod

clinical oncologist

[💙alison birtle @AlisonBirtle]

Here is a Treatment algorithm for Bone health management in patients with prostate cancer on @OpenMedicineHQ. Interactive, evidence-linked, open for discussion. Feedback welcome. #LivingAlgorithms
https://t.co/J7fMUb5ahP

[Pierre Blanchard, MD @PBlanchardMD]

Yesterday, I presented the @GETUG_Unicancer PEACE 2 trial at #ESTRO26 on the role of pelvic RT in very high risk #prostatecancer pts (staged with conventional imaging).

Twittorial below

Key conclusion: pelvic RT did not improve clinical outcomes (cPFS, MFS, PCSS, OS)...

1/n

[Alison Tree 💙 @alison_tree]

Masterclass on research design by @EmmaHall71 @ESTRO_RT If you missed it, try to watch online. Loads of important pointers for effective clinical trial creation.

[Alison Tree 💙 @alison_tree]

Great presentation by @DrSACooper @ESTRO_RT showing low adverse events in both 5 and 2 fraction MRI-guided adaptive radiotherapy (HERMES trial), with minimal impact on quality of life in both arms.

[Prof Ananya💙 @achoud72.bsky.social @achoud72]

Manchester #radbio represented at #ESTRO26 with honorary biologist @janeshortall1- the red T-shirts are special! @RT_physics @ESTRO_RT #BioCommittee @MCRCnews

[YeePei Song 🕷💙 @syeepei]

Oh lookie… the discussion on X has moved to Stockholm. @ESTRO_RT #ESTRO2026

[Sushil @Sushilberiwal]

The importance of dose homogeneity In planning for Breast RT @ACRORadOnc @ErinGillespieMD @ASTRO_org @KamravaMD @AHNtoday @ColinChampMD @Icro_Meattini @reshmajagsi
@CShahMD
https://t.co/8Lz2rzam8c

[Paolo Tarantino @PTarantinoMD]

High quality RWD to fill a relevant evidence gap: among 501 young (≤40) pts with node-positive, ER+ breast cancer who had received 5y of OFS, extending ET beyond year 5 was associated with better IBCFS & DRFS. Led by super @ValenzaCarmine! @DFCI_BreastOnc https://t.co/xbsChaRAdX

[Tom Powles @tompowles1]

What’s the future of muscle invasive bladder cancer #SimposioSOGUG25
Pathological CR rates of 57% for EVP points towards cystectomy being delayed until maximum EVP effectiveness. Also fewer patients will have cystectomy. Studies are needed to ensure this approach is safe.

[YeePei Song 🕷💙 @syeepei]

Does anyone else find the rate of completion of 6 cycles surprising? The low rate does not reflect my clinical practice at all.

@achoud72 @AlisonBirtle

[YeePei Song 🕷💙 @syeepei]

This is the important stuff. This. Not fancy expensive toxic drugs. It may be #commonsense, but it’s oddly refreshing. Thank you @csoncol

@myESMO #esmo2025

[YeePei Song 🕷💙 @syeepei]

Demise of RT in a situation like this would merely be a reflection of people’s fascination with expensive new things… at massive financial and QoL toxicities to patients. Very sad.

[Gaia Griguolo @GaiaGriguolo]

Prognostic and predictive value of KI67 before and after NAC in the MonarchE trial presented at #ESmO25

@myESMO @OncoAlert

[Hope Rugo @hoperugo]

#ESMO25 beautiful discussion by @AngieDemichele covering monarchE and Natalie. Key points below.

[Dr Sarah Sammons @drsarahsam]

My Day 1 ESMO Breast Cancer Notes to take home #bcsm @OncoAlert

[John McGrane @mcgranjo777]

Did you know the lifetime risk of prostate cancer in a black man is 1 in 4🤯

⁉️men in 🏴󠁧��󠁳󠁣󠁴󠁿are ✖️2️⃣ as likely to have advanced prostate cancer than the South of England?

Professor @frankthedoc1 is on a mission to break down testing barriers🙌🏽
@PCR_News @OncoAlert @TackleProstate

[Dra. María Natalia Gandur Quiroga @nataliagandur]

💫🌟Honored & proud to lead the #GUCancer Faculty for #ESMO25 with @ReginaBarCar 🇲🇽 & @weoncologists 🇺🇸 as we unveil our TOP 🔟 GU Abstracts 🚀 @OncoAlert
Grateful for the collaboration & excited to share the stage with brilliant minds like
🇨🇭 Dr. Gillessen
🇺🇸Dr. Agarwal
🇺🇸Dr. Zhang
🇺🇸Dr. Rini
🇺🇸Dr. Grivas
🇬🇧 Dr. Chowdhury
🇪🇸 Dr. Grande  in the Senior Faculty Band!
🔹 PSMAaddition,
🔹️ENZARAD,
🔹️CAPItello-281,
🔹️EMBARK
🔹 RAMPART,
🔹️OPTIC RCC
🔹 KEYNOTE-905,
🔹️ IMvigor011,
🔹️ALPACA & more!
See you in Berlin 🇩🇪
#ProstateCancer #KidneyCancer #BladderCancer #PenileCancer
#GUonc #OncoResearch #DelphiPicks

[Yakup Ergün @dr_yakupergun]

Tailoring Treatment to Cancer Risk and Patient Preference: The 2025 St Gallen International Breast Cancer Consensus Statement on Individualizing Therapy for Patients With Early Breast Cancer
https://t.co/5lBPzmb2AE

[Paolo Tarantino @PTarantinoMD]

One week to #ESMO25. An unprecedented ESMO conference. Seven positive press releases, anticipating the expansion of T-DXd to the curative setting, two Trop2 ADCs reaching first-line mTNBC, 2 novel ET-based combos, adjuvant CDK4/6i improving OS. See you in Berlin! #ESMOAmbassadors